Europe provides €172m for research into innovative medicines

BMJ 2011; 342 doi: (Published 10 March 2011) Cite this as: BMJ 2011;342:d1577
  1. Rory Watson
  1. 1Brussels

The second wave of medical research projects funded by the European Union’s largest biopharmaceutical public-private partnership was announced in Brussels on 8 March. The eight programmes aim to develop new treatments for cancer, rheumatoid arthritis, and infectious diseases.

The €172m (£147m; $238m) cost of the projects is being provided by the EU’s Innovative Medicines Initiative (, a partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations.

Commenting on the latest funding, Máire Geoghegan-Quinn, the European …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to to receive unlimited access to all content on for 14 days.
Sign up for a free trial